Conditioned immune response to interferon-gamma in humans

We determined whether a classical conditioning paradigm may be used to condition immunologic responses in normal human subjects receiving an optimal immunostimulating dose of recombinant human interferon-gamma (rhIFN-gamma). We conducted a placebo-controlled, double-blind study of 31 normal voluntee...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 90(1999), 2 vom: 19. Feb., Seite 173-81
1. Verfasser: Longo, D L (VerfasserIn)
Weitere Verfasser: Duffey, P L, Kopp, W C, Heyes, M P, Alvord, W G, Sharfman, W H, Schmidt, P J, Rubinow, D R, Rosenstein, D L
Format: Aufsatz
Sprache:English
Veröffentlicht: 1999
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Randomized Controlled Trial Adjuvants, Immunologic Cytokines Receptors, IgG Recombinant Proteins Neopterin 670-65-5 Propylene Glycol mehr... 6DC9Q167V3 Interferon-gamma 82115-62-6 Quinolinic Acid F6F0HK1URN
LEADER 01000naa a22002652 4500
001 NLM100141072
003 DE-627
005 20231222115526.0
007 tu
008 231222s1999 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0334.xml 
035 |a (DE-627)NLM100141072 
035 |a (NLM)10080828 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Longo, D L  |e verfasserin  |4 aut 
245 1 0 |a Conditioned immune response to interferon-gamma in humans 
264 1 |c 1999 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 29.03.1999 
500 |a Date Revised 21.11.2013 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a We determined whether a classical conditioning paradigm may be used to condition immunologic responses in normal human subjects receiving an optimal immunostimulating dose of recombinant human interferon-gamma (rhIFN-gamma). We conducted a placebo-controlled, double-blind study of 31 normal volunteers in order to determine whether an initially immune-neutral stimulus, oral propylene glycol (PG), could eventually elicit an immune response as a consequence of its being paired with a known immunostimulatory dose and schedule of rhIFN-gamma. Subjects were randomly assigned to one of three groups: (A) rhIFN-gamma injections paired with PG; (B) normal saline injections paired with PG; (C) rhIFN-gamma injections alone. During the 4-week study, subjects received progressively fewer injections so that, by the final week of the study, no injections were given and groups A and B received only PG. The principal outcome measures were serum concentrations of quinolinic acid (QUIN) and neopterin, two nonspecific but sensitive markers of immune activation, and expression of Fc receptors (CD64) on peripheral blood mononuclear cells. RhIFN-gamma injections produced significant and predictable alterations in each of the measured immune parameters. No group B subject made an immune response. Mean serum QUIN levels were significantly higher at the end of week three for subjects in the experimental condition (group A) than for subjects receiving rhIFN-gamma alone (group C) despite receiving identical doses of rhIFN-gamma. Similarly, the predicted decay in mean serum neopterin levels from the end of week 1 to the end of week 2 was seen in group C but not in group A. The exposure of group A to PG blunted the decline of CD64 expression in week four. The data suggest that the pairing of an unconditioned stimulus (rhIFN-gamma) and a conditioned stimulus (PG) permits the conditioned stimulus alone to prolong a cytokine-induced response in normal humans 
650 4 |a Clinical Trial 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 7 |a Adjuvants, Immunologic  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Receptors, IgG  |2 NLM 
650 7 |a Recombinant Proteins  |2 NLM 
650 7 |a Neopterin  |2 NLM 
650 7 |a 670-65-5  |2 NLM 
650 7 |a Propylene Glycol  |2 NLM 
650 7 |a 6DC9Q167V3  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
650 7 |a Quinolinic Acid  |2 NLM 
650 7 |a F6F0HK1URN  |2 NLM 
700 1 |a Duffey, P L  |e verfasserin  |4 aut 
700 1 |a Kopp, W C  |e verfasserin  |4 aut 
700 1 |a Heyes, M P  |e verfasserin  |4 aut 
700 1 |a Alvord, W G  |e verfasserin  |4 aut 
700 1 |a Sharfman, W H  |e verfasserin  |4 aut 
700 1 |a Schmidt, P J  |e verfasserin  |4 aut 
700 1 |a Rubinow, D R  |e verfasserin  |4 aut 
700 1 |a Rosenstein, D L  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 90(1999), 2 vom: 19. Feb., Seite 173-81  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:90  |g year:1999  |g number:2  |g day:19  |g month:02  |g pages:173-81 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 90  |j 1999  |e 2  |b 19  |c 02  |h 173-81